66. IgA腎症 IgA nephropathy Clinical trials / Disease details


臨床試験数 : 275 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000036468
2020-08-252020-08-23A Multicentre, Randomized, Controlled Trial of Rituximab in Treatment of Primary IgA NephropathyA Multicentre, Randomized, Controlled Trial of Rituximab in Treatment of Primary IgA Nephropathy IgANRituximab group:Rituximab+RASi;control group:RASi;Ruijin Hospital, Shanghai Jiaotong University School of MedicineNULLRecruiting1875BothRituximab group:58;control group:58;Phase 4China
2NCT04525729
(ClinicalTrials.gov)
July 1, 202017/8/2020Rituximab and RASi in Patients With IgANA Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA NephropathyIgA NephropathyDrug: Rituximab;Drug: RAS 2410CHENNANDongfang Hospital Affiliated to Tongji University;Shanghai Pudong New Area People's Hospital;Ruijin Hospital North Shanghai Jiao Tong University School of Medicine;Ningbo Municipal Yinzhou District No.2 Hospital;Third Affiliated Hospital, Sun Yat-Sen University;Xiamen Hongai Hospital;Sir Run Run Shaw HospitalRecruiting18 Years75 YearsAll116Phase 4China
3NCT02571842
(ClinicalTrials.gov)
January 20126/10/2015Rituximab in Recurrent IgA NephropathyA Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation PathologyRecurrent IgA NephropathyDrug: Intravenous Rituximab;Drug: ACEI/ARB and corticosteroidsChulalongkorn UniversityNULLRecruiting18 Years70 YearsBoth30Phase 4Thailand
4NCT00498368
(ClinicalTrials.gov)
February 20099/7/2007Rituximab in Progressive Immunoglobulin A (IgA) NephropathyA Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA NephropathyIgA NephropathyDrug: Intravenous Rituximab;Drug: ACE/ARB;Dietary Supplement: Omega-3 Fatty Acid Fish Oil SupplementMayo ClinicOhio State University;Stanford University;University of North Carolina, Chapel Hill;Columbia University;Genentech, Inc.;BiogenCompleted18 Years70 YearsAll34Phase 4United States